Deals
Aurobindo Said to Enter Fray for $1.5 Billion Teva Portfolio
- Teva selling European drug portfolio to appease regulators
- Indian drugmaker would finance deal with over $1 billion loan
This article is for subscribers only.
Indian drugmaker Aurobindo Pharma Ltd. is among companies considering bids for Teva Pharmaceutical Industries Ltd.’s portfolio of drugs in the U.K., Ireland and Iceland, people familiar with the matter said.
Aurobindo would finance the deal with a loan of more than $1 billion, according to one of the people, who asked not to be identified because the deliberations are private. No final decision has been made, and the company could still decide against a bid, the people said. The sale could fetch about $1.5 billion, people familiar with the matter have said previously.